February 6, 2019

Combinatorial therapy for targeting cancer stem cells in Myeloid leukaemia (ML): a pharmaceutical mixture encompassing Metformin and Navitoclax/ABT-263  inhibits cytosolic aminotransferase BCAT1 expression, increases a-ketoglutarate levels, promotes degradation of HIF1a levels, increases DNA demethylase levels, promotes hypomethylation, increases the expression of tumor suppressor genes, inhibits leukaemia-initiating potential of AML cells, promotes differentiation of AML cells, and inhibits cancer progression in AML, via up-regulation of its target gene, 6/February/2019, 11.22 pm

Introduction to what they say: A study from the Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), 69120 Heidelberg, Germany; Division of Stem […]
February 5, 2019

Combinatorial therapy for brain tumor and oesophageal squamous cell carcinoma:  A therapeutic mix encompassing metformin and navitoclax/ABT263 (MAN) inhibits the expression of Integrin a7 (ITGA7), impairs laminin-induced/FAK-mediated signalling, inhibits the proliferation of glioblastoma and oesophageal squamous cell carcinoma stem cells, suppresses tumor cell migration, reduces metastasis and prolongs survival, via down-regulation of its target gene, 5/February/2019, 6.21 am

Introduction: What they say: A study from the Institute of General Pathology, Università Cattolica del Sacro Cuore and Fondazione Policlinico Universitario A. Gemelli, 00168 Rome, Italy; […]
February 3, 2019

Combinatorial therapy for gynecologic cancers: A therapeutic mix encompassing Metformin and Navitoclax (ABT-263) (MAN) inhibits the expression of HDAC6, acetylates tumor suppressor proteins, activates tumor suppressor function, and stifles the progression of ARID1A-mutated ovarian cancers, via up-regulation of its target gene, 3/February/2019, 11.22 pm

Introduction: What they say:  A study from Gene Expression and Regulation Program, The Wistar Institute, Philadelphia, Pennsylvania 19104, USA shows that “ARID1A-mutated ovarian cancers depend on […]
February 3, 2019

Molecular therapy for safeguarding your heart against cardiac dysfunction: Rebamipide (Trade names: Mucosta, Rebagen, and Rebagit) , a gastrointestinal medication used in the treatment of gastroduodenal ulcers, and gastritis, decreases tumor suppressor Mir-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 3/February/2019, 11.10 pm

Introduction: What they say: A recent study from Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA; Key Laboratory […]